Hepatitis B Vaccine
Dynavax initiates pivotal Phase 3 trial for Heplisav, hepatitis B vaccine
Published in Hepatitis Weekly, January 15th, 2007
Sites in the United States and in Europe are scheduled to participate in the study and are expected to begin dosing patients in early 2007. The multicenter Phase 3 trial, known as PHAST (Phase 3 HeplisAv Short-regimen Trial), will compare a two-dose regimen of Heplisav administered at 0- and 1-month to the conventional three-dose regimen of Engerix-B. The enrollment target of the study is 1,740 subjects, ages 11 to 55 years.
"In several previous clinical studies, Heplisav has been shown to...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2007-01-15)
More Articles from Hepatitis Weekly
- Hepatitis C Therapy
Phase III trial of Albuferon/ribavirin combo underway in treatment-naive HCV patients - Hepatitis C Therapy
Results of first interim safety, antiviral analysis of HVC protease inhibitor reported - Hepatitis A Virus
New findings from School of Public Health in the area of hepatitis a virus published - Hepatitis B Virus
Investigators at Virgen of la Arrixaca University release new data on hepatitis b virus - Hepatitis B Virus
Recent findings from University Hospital, Department of Molecular Pathology highlight research in hepatitis b virus - Hepatitis B Virus
Reports from Hospital advance knowledge in hepatitis b virus - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
